Book contents
- Seminars in Clinical Psychopharmacology
- College Seminars Series
- Seminars in Clinical Psychopharmacology
- Copyright page
- Contents
- Contributors
- Foreword
- Preface
- Editor’s Note on Nomenclature
- Neuroscience-Based Nomenclature Glossary
- Abbreviations
- Part 1 Basic Science and General Principles
- Part 2 Psychopharmacology of the Main Psychotropic Drug Groups
- Chapter 7 Drugs to Treat Depression
- Chapter 8 Drugs to Treat Anxiety and Insomnia
- Chapter 9 Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than Clozapine)
- Chapter 10 Clozapine
- Chapter 11 Lithium
- Chapter 12 Anticonvulsants for Mental Disorders: Valproate, Lamotrigine, Carbamazepine and Oxcarbazepine
- Chapter 13 Drugs to Treat Attention Deficit Hyperactivity Disorder (ADHD)
- Chapter 14 Drugs to Treat Dementia
- Chapter 15 Drugs to Treat Substance Use Disorders
- Chapter 16 Electroconvulsive Therapy and Neuromodulation Therapies
- Part 3 Specific Therapeutic Areas
- Index
- References
Chapter 10 - Clozapine
from Part 2 - Psychopharmacology of the Main Psychotropic Drug Groups
Published online by Cambridge University Press: 29 May 2020
- Seminars in Clinical Psychopharmacology
- College Seminars Series
- Seminars in Clinical Psychopharmacology
- Copyright page
- Contents
- Contributors
- Foreword
- Preface
- Editor’s Note on Nomenclature
- Neuroscience-Based Nomenclature Glossary
- Abbreviations
- Part 1 Basic Science and General Principles
- Part 2 Psychopharmacology of the Main Psychotropic Drug Groups
- Chapter 7 Drugs to Treat Depression
- Chapter 8 Drugs to Treat Anxiety and Insomnia
- Chapter 9 Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than Clozapine)
- Chapter 10 Clozapine
- Chapter 11 Lithium
- Chapter 12 Anticonvulsants for Mental Disorders: Valproate, Lamotrigine, Carbamazepine and Oxcarbazepine
- Chapter 13 Drugs to Treat Attention Deficit Hyperactivity Disorder (ADHD)
- Chapter 14 Drugs to Treat Dementia
- Chapter 15 Drugs to Treat Substance Use Disorders
- Chapter 16 Electroconvulsive Therapy and Neuromodulation Therapies
- Part 3 Specific Therapeutic Areas
- Index
- References
Summary
Clozapine is a dopamine receptor antagonist that blocks a range of other monoamine receptors and may have some effects on the glutamatergic system. There is evidence that it has better efficacy and effectiveness than other dopamine antagonists in treating schizophrenia that has failed to respond to other dopamine receptor antagonists. It appears to reduce impulsive behaviours such as violence (Frogley et al., 2011), self-harm (Meltzer et al., 2003) and substance misuse (Lalanne et al., 2016) and to have mood-stabilizing properties (Chang et al., 2006). In the UK it is licensed for three indications: (i) treatment-resistant schizophrenia, (ii) for treating schizophrenia when other antipsychotics have led to severe neurological adverse reactions and (iii) treating psychosis associated with Parkinson’s disease where standard treatment has failed (electronic Medicines Compendium, 2019).
- Type
- Chapter
- Information
- Seminars in Clinical Psychopharmacology , pp. 326 - 349Publisher: Cambridge University PressPrint publication year: 2020